Physician profile
Alison Nolan
NPI 1982609764
$1,161.30
in general payments reported to CMS, 2019-2025
14 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $455 · 2023: $266 · 2024: $97.63 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $465.20 | 2021-2024 | Gattex |
| Novo Nordisk INC | $152.67 | 2021-2024 | Wegovy, Saxenda |
| Revance Therapeutics, INC. | $114.28 | 2025 | Daxxify |
| Abbvie INC. | $109.70 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $85.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.66 | 2022 | |
| Currax Pharmaceuticals LLC | $32.41 | 2021-2024 | Contrave, Onzetra Xsail |
| Boston Scientific Corporation | $20.13 | 2023 | |
| Endo Pharmaceuticals INC. | $19.97 | 2022 | |
| Reshape Lifesciences INC. | $19.58 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $17.85 | 2023 | Imcivree |
| Lilly USA, LLC | $14.33 | 2023 | Zepbound |
| Redhill Biopharma INC. | $13.21 | 2021 | |
| Innocoll Pharmaceuticals Limited | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.